Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms

SOYER N., HAZNEDAROĞLU İ. C., Comert M., Cekdemir D., YILMAZ M., ÜNAL A., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.1, ss.27-33, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjh.2016.0005
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.27-33
  • Anahtar Kelimeler: Chronic myeloproliferative neoplasms, Treatment, Survival, JAK2 mutation, WORLD-HEALTH-ORGANIZATION, POLYCYTHEMIA-VERA, ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS, PROGNOSTIC-FACTORS, LIFE EXPECTANCY, RISK-STRATIFICATION, UNITED-STATES, SURVIVAL, THROMBOSIS
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia-negative malignancies characterized by a clonal proliferation of one or several lineages. The aim of this report was to determine the demographic features, disease characteristics, treatment strategies, and survival rates of patients with CMPNs in Turkey.